Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study [Corrigendum]
Casas A, Montes de Oca M, Menezes AMB, Wehrmeister FC, Lopez Varela MV, Mendoza L, Ramírez L, Miravitlles M. Int J Chron Obstruct Pulmon Dis. 2018;13:1545–1556.
Page 1552, Disclosure, the text “AM has been paid for her work as a statistician for the LASSYC study. LR is an employee of AstraZeneca. The other authors report no conflicts of interest in this work” should read “AMM has been paid by AstraZeneca and GlaxoSmithKline for her work as a statistician for the LASSYC and PLATINIO studies, respectively. LR is an employee of AstraZeneca.
MM has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, CSL Behring, Grifols and Novartis; consultancy fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratories Esteve, Mereo BioPharm, Verona Pharma, pH
Pharma, Novartis and Grifols; and research grants from GlaxoSmithKline and Grifols. The authors report no other conflicts of interest in this work”.
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]